Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Genomics | 42 | 2023 | 5722 | 2.450 |
Why?
|
Drug Resistance, Neoplasm | 34 | 2021 | 5169 | 2.450 |
Why?
|
Carcinoma, Renal Cell | 25 | 2023 | 3130 | 2.100 |
Why?
|
Neoplasms | 42 | 2024 | 21672 | 2.000 |
Why?
|
Kidney Neoplasms | 25 | 2023 | 4245 | 1.890 |
Why?
|
Prostatic Neoplasms | 32 | 2024 | 11074 | 1.750 |
Why?
|
Immunotherapy | 24 | 2022 | 4440 | 1.650 |
Why?
|
Medical Oncology | 11 | 2024 | 2265 | 1.580 |
Why?
|
Germ-Line Mutation | 17 | 2022 | 1787 | 1.530 |
Why?
|
Receptors, Androgen | 11 | 2022 | 1057 | 1.500 |
Why?
|
Antigens, Neoplasm | 9 | 2019 | 1987 | 1.390 |
Why?
|
Mutation | 71 | 2023 | 29784 | 1.330 |
Why?
|
Urinary Bladder Neoplasms | 13 | 2023 | 2237 | 1.270 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 4 | 2023 | 484 | 1.190 |
Why?
|
DNA Repair | 11 | 2021 | 2046 | 1.170 |
Why?
|
Melanoma | 15 | 2021 | 5475 | 1.090 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 7 | 2023 | 105 | 1.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 20 | 2022 | 3598 | 1.020 |
Why?
|
Antigen Presentation | 7 | 2021 | 1284 | 1.000 |
Why?
|
Antineoplastic Agents | 24 | 2023 | 13668 | 0.970 |
Why?
|
DNA Repair-Deficiency Disorders | 2 | 2021 | 29 | 0.960 |
Why?
|
Proto-Oncogene Proteins B-raf | 8 | 2020 | 2041 | 0.950 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 23 | 2022 | 11493 | 0.930 |
Why?
|
DNA Mutational Analysis | 10 | 2022 | 4188 | 0.900 |
Why?
|
Androgen Antagonists | 6 | 2023 | 1361 | 0.880 |
Why?
|
Tumor Microenvironment | 14 | 2024 | 3584 | 0.870 |
Why?
|
Urologic Neoplasms | 5 | 2020 | 316 | 0.860 |
Why?
|
Genome, Human | 13 | 2021 | 4420 | 0.820 |
Why?
|
Gene Expression Regulation, Neoplastic | 16 | 2022 | 8426 | 0.790 |
Why?
|
Neurofibromin 1 | 2 | 2020 | 196 | 0.780 |
Why?
|
Carcinoma | 3 | 2023 | 2375 | 0.750 |
Why?
|
Sequence Analysis, DNA | 15 | 2021 | 4803 | 0.740 |
Why?
|
Humans | 219 | 2024 | 744220 | 0.720 |
Why?
|
Lung Neoplasms | 13 | 2023 | 13096 | 0.710 |
Why?
|
PTEN Phosphohydrolase | 6 | 2020 | 1143 | 0.690 |
Why?
|
Gene Expression Profiling | 17 | 2021 | 9438 | 0.680 |
Why?
|
Gene Fusion | 2 | 2022 | 371 | 0.670 |
Why?
|
Testicular Neoplasms | 4 | 2021 | 761 | 0.670 |
Why?
|
GTP Phosphohydrolases | 3 | 2021 | 508 | 0.670 |
Why?
|
Genetic Testing | 4 | 2020 | 3443 | 0.660 |
Why?
|
Protein Kinase Inhibitors | 13 | 2022 | 5529 | 0.660 |
Why?
|
Artificial Intelligence | 5 | 2024 | 2213 | 0.640 |
Why?
|
Cisplatin | 6 | 2023 | 1642 | 0.630 |
Why?
|
Neoadjuvant Therapy | 10 | 2022 | 2726 | 0.620 |
Why?
|
Data Display | 1 | 2018 | 182 | 0.610 |
Why?
|
Radiation Tolerance | 2 | 2019 | 484 | 0.600 |
Why?
|
Databases, Genetic | 10 | 2021 | 1782 | 0.600 |
Why?
|
Neoplasm Metastasis | 20 | 2021 | 4841 | 0.600 |
Why?
|
Skin Neoplasms | 8 | 2020 | 5670 | 0.580 |
Why?
|
Microsatellite Repeats | 2 | 2018 | 802 | 0.570 |
Why?
|
Leiomyosarcoma | 2 | 2019 | 477 | 0.550 |
Why?
|
Oncogenes | 2 | 2022 | 1265 | 0.550 |
Why?
|
Inheritance Patterns | 1 | 2018 | 340 | 0.530 |
Why?
|
Introns | 1 | 2018 | 991 | 0.530 |
Why?
|
Tumor Suppressor Protein p53 | 10 | 2022 | 2948 | 0.530 |
Why?
|
Adenocarcinoma | 8 | 2020 | 6352 | 0.520 |
Why?
|
Genome | 4 | 2020 | 1808 | 0.520 |
Why?
|
Janus Kinase 3 | 1 | 2015 | 78 | 0.510 |
Why?
|
Paternal Exposure | 1 | 2015 | 89 | 0.510 |
Why?
|
Biomarkers, Pharmacological | 1 | 2015 | 162 | 0.500 |
Why?
|
Genetic Predisposition to Disease | 20 | 2022 | 17449 | 0.490 |
Why?
|
Epitopes | 2 | 2018 | 2571 | 0.490 |
Why?
|
Male | 107 | 2024 | 350027 | 0.490 |
Why?
|
Germ Cells | 7 | 2022 | 631 | 0.480 |
Why?
|
Prostate-Specific Antigen | 4 | 2023 | 2478 | 0.470 |
Why?
|
Drug Synergism | 2 | 2016 | 1791 | 0.470 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1782 | 0.460 |
Why?
|
Tongue Neoplasms | 1 | 2015 | 180 | 0.460 |
Why?
|
Immunologic Factors | 3 | 2022 | 1582 | 0.450 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 489 | 0.450 |
Why?
|
Sarcoma | 2 | 2022 | 1897 | 0.450 |
Why?
|
Cell Line, Tumor | 25 | 2022 | 16687 | 0.430 |
Why?
|
Repressor Proteins | 2 | 2021 | 3023 | 0.430 |
Why?
|
TOR Serine-Threonine Kinases | 7 | 2020 | 2108 | 0.430 |
Why?
|
Urothelium | 1 | 2014 | 277 | 0.420 |
Why?
|
Cell Survival | 2 | 2021 | 5881 | 0.400 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2014 | 414 | 0.400 |
Why?
|
Molecular Targeted Therapy | 10 | 2022 | 2727 | 0.400 |
Why?
|
Urinary Bladder | 1 | 2017 | 1172 | 0.390 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 5867 | 0.390 |
Why?
|
Thyroid Neoplasms | 2 | 2022 | 2281 | 0.380 |
Why?
|
Bone Neoplasms | 4 | 2018 | 2525 | 0.380 |
Why?
|
Phosphatidylinositol 3-Kinases | 7 | 2018 | 2938 | 0.370 |
Why?
|
Mouth Neoplasms | 2 | 2018 | 601 | 0.370 |
Why?
|
Carcinoma, Transitional Cell | 4 | 2019 | 802 | 0.370 |
Why?
|
Signal Transduction | 16 | 2021 | 23404 | 0.360 |
Why?
|
Prostate | 3 | 2022 | 1773 | 0.360 |
Why?
|
Colorectal Neoplasms | 7 | 2021 | 6773 | 0.360 |
Why?
|
Rectal Neoplasms | 1 | 2019 | 1203 | 0.360 |
Why?
|
Furans | 2 | 2021 | 194 | 0.360 |
Why?
|
Ketones | 2 | 2021 | 188 | 0.360 |
Why?
|
Transcription, Genetic | 4 | 2021 | 7723 | 0.340 |
Why?
|
Endogenous Retroviruses | 2 | 2022 | 112 | 0.340 |
Why?
|
DNA, Neoplasm | 5 | 2018 | 1758 | 0.340 |
Why?
|
Nuclear Proteins | 4 | 2023 | 5853 | 0.330 |
Why?
|
Ovarian Neoplasms | 2 | 2023 | 4837 | 0.330 |
Why?
|
Neoplasm Proteins | 5 | 2020 | 3703 | 0.330 |
Why?
|
Models, Genetic | 1 | 2018 | 3494 | 0.310 |
Why?
|
Biopsy | 6 | 2021 | 6757 | 0.310 |
Why?
|
Treatment Refusal | 1 | 2011 | 421 | 0.310 |
Why?
|
T-Lymphocytes | 7 | 2023 | 10182 | 0.300 |
Why?
|
Software | 3 | 2020 | 4442 | 0.300 |
Why?
|
Uterine Neoplasms | 1 | 2017 | 1513 | 0.300 |
Why?
|
Middle Aged | 57 | 2023 | 213367 | 0.300 |
Why?
|
Membrane Proteins | 4 | 2021 | 7879 | 0.300 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2024 | 4033 | 0.300 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 7 | 2022 | 1039 | 0.290 |
Why?
|
Aged | 50 | 2023 | 163253 | 0.290 |
Why?
|
Gene Dosage | 4 | 2021 | 1251 | 0.290 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 6 | 2023 | 1692 | 0.290 |
Why?
|
Anus Neoplasms | 2 | 2024 | 332 | 0.290 |
Why?
|
Physician-Patient Relations | 2 | 2011 | 3227 | 0.290 |
Why?
|
Neoplasm Invasiveness | 7 | 2023 | 3614 | 0.280 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 5221 | 0.280 |
Why?
|
Phenylthiohydantoin | 4 | 2021 | 192 | 0.280 |
Why?
|
Sulfonamides | 4 | 2018 | 1940 | 0.280 |
Why?
|
Prostatectomy | 5 | 2023 | 1887 | 0.270 |
Why?
|
Female | 68 | 2023 | 380197 | 0.270 |
Why?
|
DNA Mismatch Repair | 2 | 2019 | 426 | 0.270 |
Why?
|
Computer Simulation | 2 | 2018 | 6196 | 0.260 |
Why?
|
Melanoma, Experimental | 2 | 2020 | 561 | 0.260 |
Why?
|
DNA Copy Number Variations | 8 | 2023 | 1940 | 0.260 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2018 | 933 | 0.260 |
Why?
|
Patient Care | 1 | 2011 | 640 | 0.260 |
Why?
|
Neuroendocrine Tumors | 3 | 2023 | 594 | 0.260 |
Why?
|
Tumor Escape | 2 | 2018 | 349 | 0.260 |
Why?
|
Cohort Studies | 17 | 2022 | 40559 | 0.250 |
Why?
|
Death | 1 | 2009 | 678 | 0.250 |
Why?
|
Colonic Neoplasms | 1 | 2016 | 2538 | 0.240 |
Why?
|
Transcription Factors | 9 | 2023 | 12207 | 0.240 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2020 | 3557 | 0.240 |
Why?
|
DNA Damage | 4 | 2022 | 2432 | 0.240 |
Why?
|
Genome-Wide Association Study | 6 | 2022 | 12264 | 0.240 |
Why?
|
Cyclic AMP Response Element-Binding Protein A | 2 | 2022 | 21 | 0.230 |
Why?
|
Cell Cycle Proteins | 3 | 2021 | 3461 | 0.220 |
Why?
|
Antibodies, Monoclonal | 4 | 2018 | 9275 | 0.220 |
Why?
|
Platinum | 2 | 2022 | 233 | 0.220 |
Why?
|
Breast Neoplasms | 8 | 2023 | 20817 | 0.220 |
Why?
|
Nitriles | 4 | 2021 | 952 | 0.220 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2022 | 4477 | 0.220 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2021 | 250 | 0.220 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 3 | 2021 | 647 | 0.210 |
Why?
|
Aged, 80 and over | 23 | 2022 | 57768 | 0.210 |
Why?
|
Stomach Neoplasms | 2 | 2023 | 1333 | 0.210 |
Why?
|
Benzamides | 4 | 2021 | 1378 | 0.210 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2022 | 42 | 0.210 |
Why?
|
Microphthalmia-Associated Transcription Factor | 2 | 2022 | 251 | 0.210 |
Why?
|
MAP Kinase Signaling System | 4 | 2018 | 1525 | 0.210 |
Why?
|
Computational Biology | 5 | 2020 | 3523 | 0.210 |
Why?
|
Proto-Oncogene Proteins | 3 | 2021 | 4553 | 0.210 |
Why?
|
Antigen-Antibody Complex | 1 | 2024 | 517 | 0.210 |
Why?
|
Attitude to Health | 1 | 2011 | 2053 | 0.200 |
Why?
|
Genes, Neoplasm | 3 | 2018 | 376 | 0.200 |
Why?
|
Genetic Heterogeneity | 4 | 2021 | 733 | 0.200 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2021 | 203 | 0.190 |
Why?
|
Adult | 37 | 2022 | 214035 | 0.190 |
Why?
|
Head and Neck Neoplasms | 1 | 2015 | 2732 | 0.190 |
Why?
|
Microsatellite Instability | 3 | 2020 | 684 | 0.190 |
Why?
|
Intestinal Neoplasms | 1 | 2023 | 319 | 0.190 |
Why?
|
Osteosarcoma | 2 | 2018 | 881 | 0.190 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2020 | 890 | 0.190 |
Why?
|
Multiple Myeloma | 4 | 2020 | 5180 | 0.190 |
Why?
|
Alkylating Agents | 1 | 2021 | 139 | 0.190 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2021 | 114 | 0.190 |
Why?
|
False Positive Reactions | 2 | 2016 | 981 | 0.190 |
Why?
|
Androgens | 3 | 2023 | 1279 | 0.190 |
Why?
|
Estrogen Receptor alpha | 1 | 2014 | 577 | 0.190 |
Why?
|
Tumor Suppressor Proteins | 5 | 2021 | 2848 | 0.190 |
Why?
|
Pyrimidinones | 2 | 2020 | 371 | 0.180 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2021 | 200 | 0.180 |
Why?
|
Therapies, Investigational | 1 | 2021 | 112 | 0.180 |
Why?
|
Sesquiterpenes | 1 | 2020 | 177 | 0.180 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2021 | 315 | 0.170 |
Why?
|
Morpholines | 2 | 2020 | 573 | 0.170 |
Why?
|
Adaptation, Psychological | 1 | 2010 | 2576 | 0.170 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2020 | 130 | 0.170 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 407 | 0.170 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 315 | 0.170 |
Why?
|
Disease Progression | 8 | 2023 | 13280 | 0.170 |
Why?
|
Gene Amplification | 2 | 2021 | 1062 | 0.170 |
Why?
|
Paraffin Embedding | 1 | 2020 | 299 | 0.170 |
Why?
|
Carboplatin | 1 | 2022 | 800 | 0.170 |
Why?
|
Tissue Fixation | 1 | 2020 | 241 | 0.170 |
Why?
|
Histone Demethylases | 2 | 2020 | 321 | 0.170 |
Why?
|
raf Kinases | 2 | 2016 | 122 | 0.170 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2018 | 322 | 0.170 |
Why?
|
Aminopyridines | 2 | 2020 | 542 | 0.170 |
Why?
|
Cardiology | 1 | 2010 | 1668 | 0.170 |
Why?
|
Androgen Receptor Antagonists | 1 | 2019 | 114 | 0.170 |
Why?
|
Muscles | 5 | 2022 | 1622 | 0.170 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 104 | 0.170 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 212 | 0.170 |
Why?
|
Neoplasm Staging | 7 | 2019 | 11007 | 0.170 |
Why?
|
Survival Analysis | 8 | 2021 | 10250 | 0.160 |
Why?
|
Biology | 1 | 2021 | 294 | 0.160 |
Why?
|
Watchful Waiting | 1 | 2023 | 491 | 0.160 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 97 | 0.160 |
Why?
|
Algorithms | 4 | 2018 | 13885 | 0.160 |
Why?
|
RNA-Induced Silencing Complex | 1 | 2018 | 55 | 0.160 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2022 | 794 | 0.160 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2018 | 535 | 0.160 |
Why?
|
Epigenesis, Genetic | 4 | 2021 | 3646 | 0.160 |
Why?
|
Quality Control | 1 | 2021 | 843 | 0.160 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2020 | 177 | 0.160 |
Why?
|
Gene Library | 1 | 2021 | 1076 | 0.160 |
Why?
|
Proteome | 2 | 2021 | 1798 | 0.160 |
Why?
|
Prospective Studies | 11 | 2024 | 53280 | 0.150 |
Why?
|
Spliceosomes | 1 | 2018 | 110 | 0.150 |
Why?
|
Pyrazoles | 2 | 2020 | 1973 | 0.150 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 2 | 2022 | 170 | 0.150 |
Why?
|
Terminal Care | 1 | 2009 | 1694 | 0.150 |
Why?
|
Epitope Mapping | 1 | 2018 | 311 | 0.150 |
Why?
|
DNA-Binding Proteins | 6 | 2022 | 9647 | 0.150 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2021 | 332 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2021 | 9230 | 0.150 |
Why?
|
Phenotype | 6 | 2023 | 16365 | 0.150 |
Why?
|
Electron Transport Complex I | 1 | 2018 | 140 | 0.150 |
Why?
|
Students, Medical | 1 | 2010 | 1862 | 0.150 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2017 | 51 | 0.150 |
Why?
|
Cullin Proteins | 1 | 2018 | 180 | 0.150 |
Why?
|
Nucleotides | 1 | 2020 | 464 | 0.150 |
Why?
|
Cystectomy | 2 | 2023 | 686 | 0.150 |
Why?
|
Immunity, Cellular | 2 | 2020 | 1607 | 0.150 |
Why?
|
Prognosis | 15 | 2023 | 29050 | 0.140 |
Why?
|
Adenoma, Oxyphilic | 1 | 2018 | 143 | 0.140 |
Why?
|
Treatment Outcome | 15 | 2023 | 63119 | 0.140 |
Why?
|
Animals | 24 | 2023 | 168788 | 0.140 |
Why?
|
Receptors, Estrogen | 3 | 2021 | 2186 | 0.140 |
Why?
|
Bone Marrow Neoplasms | 1 | 2017 | 104 | 0.140 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2021 | 388 | 0.140 |
Why?
|
Electronic Health Records | 6 | 2023 | 4463 | 0.140 |
Why?
|
Radiation Oncology | 1 | 2022 | 555 | 0.140 |
Why?
|
Liposarcoma | 1 | 2019 | 333 | 0.140 |
Why?
|
Quinoxalines | 1 | 2018 | 290 | 0.140 |
Why?
|
Survival Rate | 6 | 2021 | 12781 | 0.140 |
Why?
|
Indoles | 2 | 2015 | 1838 | 0.140 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 713 | 0.140 |
Why?
|
Data Mining | 1 | 2021 | 537 | 0.130 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2016 | 223 | 0.130 |
Why?
|
Glutathione | 1 | 2018 | 588 | 0.130 |
Why?
|
Immunity | 2 | 2019 | 1012 | 0.130 |
Why?
|
Lysine | 1 | 2020 | 1008 | 0.130 |
Why?
|
Immunologic Surveillance | 1 | 2016 | 93 | 0.130 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2015 | 337 | 0.130 |
Why?
|
Immunohistochemistry | 5 | 2020 | 11368 | 0.130 |
Why?
|
Cerebellar Neoplasms | 1 | 2020 | 587 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2023 | 3506 | 0.130 |
Why?
|
Oximes | 2 | 2013 | 311 | 0.130 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2020 | 1724 | 0.130 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2021 | 1509 | 0.130 |
Why?
|
Proteins | 2 | 2021 | 6101 | 0.130 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2016 | 261 | 0.130 |
Why?
|
Stress, Psychological | 1 | 2010 | 4245 | 0.130 |
Why?
|
Medulloblastoma | 1 | 2020 | 683 | 0.130 |
Why?
|
Mice | 18 | 2023 | 81178 | 0.130 |
Why?
|
Pyrrolidinones | 1 | 2015 | 117 | 0.130 |
Why?
|
Oncogene Proteins | 2 | 2020 | 749 | 0.130 |
Why?
|
Deoxycytidine | 2 | 2017 | 825 | 0.120 |
Why?
|
Uveal Neoplasms | 1 | 2017 | 310 | 0.120 |
Why?
|
HEK293 Cells | 2 | 2014 | 4201 | 0.120 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 1519 | 0.120 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2019 | 635 | 0.120 |
Why?
|
RNA | 3 | 2022 | 2749 | 0.120 |
Why?
|
Radiosurgery | 1 | 2024 | 1328 | 0.120 |
Why?
|
Mitochondria | 2 | 2018 | 3520 | 0.120 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 684 | 0.120 |
Why?
|
Pyrimidines | 2 | 2018 | 2940 | 0.120 |
Why?
|
Documentation | 1 | 2020 | 869 | 0.120 |
Why?
|
Reproducibility of Results | 4 | 2021 | 19907 | 0.120 |
Why?
|
Teratoma | 1 | 2016 | 387 | 0.120 |
Why?
|
Androstenes | 2 | 2019 | 169 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1581 | 0.120 |
Why?
|
Gene Silencing | 1 | 2020 | 1538 | 0.120 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2013 | 96 | 0.120 |
Why?
|
Mass Screening | 1 | 2009 | 5252 | 0.110 |
Why?
|
Phylogeny | 2 | 2021 | 2803 | 0.110 |
Why?
|
History, 21st Century | 1 | 2019 | 1534 | 0.110 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2012 | 30 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2023 | 1660 | 0.110 |
Why?
|
Comprehension | 1 | 2018 | 610 | 0.110 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2018 | 736 | 0.110 |
Why?
|
Incidental Findings | 2 | 2016 | 689 | 0.110 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2013 | 708 | 0.110 |
Why?
|
Aptamers, Nucleotide | 1 | 2013 | 166 | 0.100 |
Why?
|
Testis | 1 | 2015 | 800 | 0.100 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2015 | 504 | 0.100 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15070 | 0.100 |
Why?
|
Practice Guidelines as Topic | 1 | 2009 | 7281 | 0.100 |
Why?
|
Mutation, Missense | 2 | 2018 | 2563 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1587 | 0.100 |
Why?
|
Ubiquitin Thiolesterase | 3 | 2021 | 449 | 0.100 |
Why?
|
Mediator Complex | 1 | 2012 | 109 | 0.100 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2018 | 1860 | 0.100 |
Why?
|
Spermatozoa | 1 | 2015 | 625 | 0.100 |
Why?
|
Microtubule-Associated Proteins | 2 | 2018 | 1086 | 0.100 |
Why?
|
Anecdotes as Topic | 1 | 2011 | 57 | 0.100 |
Why?
|
Young Adult | 12 | 2022 | 56436 | 0.100 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2017 | 1366 | 0.100 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2020 | 5442 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3474 | 0.100 |
Why?
|
Evolution, Molecular | 2 | 2016 | 1939 | 0.100 |
Why?
|
Mice, Inbred NOD | 3 | 2020 | 1877 | 0.100 |
Why?
|
Metabolomics | 1 | 2019 | 1483 | 0.100 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 7908 | 0.100 |
Why?
|
Blood Proteins | 1 | 2016 | 1123 | 0.100 |
Why?
|
Conserved Sequence | 1 | 2014 | 1202 | 0.100 |
Why?
|
Cancer Vaccines | 1 | 2018 | 1024 | 0.090 |
Why?
|
Paracentesis | 1 | 2011 | 95 | 0.090 |
Why?
|
Hematopoiesis | 1 | 2020 | 2069 | 0.090 |
Why?
|
Risk Factors | 7 | 2023 | 72280 | 0.090 |
Why?
|
Retrospective Studies | 11 | 2024 | 77426 | 0.090 |
Why?
|
Imidazoles | 2 | 2013 | 1206 | 0.090 |
Why?
|
Sick Role | 1 | 2011 | 237 | 0.090 |
Why?
|
Humanism | 1 | 2011 | 89 | 0.090 |
Why?
|
Quinolines | 1 | 2015 | 730 | 0.090 |
Why?
|
Proteomics | 2 | 2021 | 3637 | 0.090 |
Why?
|
Internship and Residency | 1 | 2010 | 5787 | 0.090 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 4929 | 0.090 |
Why?
|
Histones | 1 | 2020 | 2600 | 0.090 |
Why?
|
HLA Antigens | 1 | 2015 | 1382 | 0.090 |
Why?
|
Lymphocytes | 1 | 2018 | 2617 | 0.090 |
Why?
|
NF-E2-Related Factor 2 | 2 | 2023 | 377 | 0.090 |
Why?
|
Protein Biosynthesis | 1 | 2017 | 2126 | 0.090 |
Why?
|
Androstenols | 1 | 2009 | 25 | 0.090 |
Why?
|
Information Storage and Retrieval | 1 | 2015 | 824 | 0.090 |
Why?
|
Protein Conformation | 2 | 2014 | 4012 | 0.090 |
Why?
|
Remission Induction | 1 | 2015 | 2389 | 0.090 |
Why?
|
Ketoconazole | 1 | 2009 | 95 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2019 | 2942 | 0.080 |
Why?
|
Risk | 1 | 2021 | 9685 | 0.080 |
Why?
|
Mice, Nude | 3 | 2018 | 3689 | 0.080 |
Why?
|
Enzyme Activation | 1 | 2015 | 3701 | 0.080 |
Why?
|
Neutrophils | 2 | 2019 | 3717 | 0.080 |
Why?
|
Natural Language Processing | 3 | 2021 | 1040 | 0.080 |
Why?
|
Pyrroles | 1 | 2015 | 1143 | 0.080 |
Why?
|
Homeodomain Proteins | 1 | 2018 | 2422 | 0.080 |
Why?
|
Pedigree | 1 | 2016 | 4648 | 0.080 |
Why?
|
Research Design | 2 | 2021 | 5987 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2014 | 2886 | 0.080 |
Why?
|
Nerve Tissue Proteins | 1 | 2021 | 4465 | 0.080 |
Why?
|
Sequence Analysis | 2 | 2022 | 256 | 0.080 |
Why?
|
RNA, Double-Stranded | 2 | 2020 | 290 | 0.080 |
Why?
|
Hormones | 2 | 2022 | 887 | 0.080 |
Why?
|
Survivors | 1 | 2018 | 2291 | 0.080 |
Why?
|
Chromosome Mapping | 1 | 2016 | 4742 | 0.080 |
Why?
|
Quality of Life | 3 | 2024 | 12805 | 0.080 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 704 | 0.080 |
Why?
|
Models, Molecular | 2 | 2014 | 5458 | 0.070 |
Why?
|
Sirolimus | 1 | 2014 | 1563 | 0.070 |
Why?
|
Pyridines | 2 | 2018 | 2822 | 0.070 |
Why?
|
Professional-Family Relations | 1 | 2011 | 482 | 0.070 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2016 | 1052 | 0.070 |
Why?
|
Sequence Analysis, RNA | 3 | 2020 | 2013 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2015 | 2503 | 0.070 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2020 | 290 | 0.070 |
Why?
|
Alleles | 1 | 2017 | 6938 | 0.070 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 1814 | 0.070 |
Why?
|
Genetic Variation | 3 | 2016 | 6546 | 0.070 |
Why?
|
Receptors, Progesterone | 2 | 2021 | 1097 | 0.070 |
Why?
|
Medical Informatics | 1 | 2013 | 743 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 25043 | 0.070 |
Why?
|
DNA Helicases | 2 | 2023 | 861 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2011 | 1849 | 0.070 |
Why?
|
Radiography | 2 | 2014 | 7022 | 0.070 |
Why?
|
Cyclin D1 | 2 | 2018 | 462 | 0.070 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5257 | 0.070 |
Why?
|
Professional-Patient Relations | 1 | 2011 | 737 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14726 | 0.060 |
Why?
|
Endometrial Neoplasms | 1 | 2014 | 1353 | 0.060 |
Why?
|
Pteridines | 1 | 2014 | 45 | 0.060 |
Why?
|
Indazoles | 2 | 2018 | 287 | 0.060 |
Why?
|
Phosphoproteins | 1 | 2013 | 2440 | 0.060 |
Why?
|
Child | 6 | 2023 | 77679 | 0.060 |
Why?
|
RNA-Binding Proteins | 1 | 2013 | 1903 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5138 | 0.060 |
Why?
|
Decision Support Systems, Clinical | 1 | 2013 | 1162 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2020 | 15525 | 0.060 |
Why?
|
Receptors, Immunologic | 2 | 2020 | 1423 | 0.060 |
Why?
|
Mice, SCID | 2 | 2020 | 2716 | 0.060 |
Why?
|
RNA Interference | 1 | 2013 | 2890 | 0.060 |
Why?
|
Phosphorylation | 1 | 2015 | 8437 | 0.060 |
Why?
|
Receptor, erbB-2 | 3 | 2020 | 2416 | 0.060 |
Why?
|
Histone-Lysine N-Methyltransferase | 2 | 2020 | 671 | 0.060 |
Why?
|
Up-Regulation | 2 | 2023 | 4217 | 0.060 |
Why?
|
Interpersonal Relations | 1 | 2011 | 1424 | 0.060 |
Why?
|
Castration | 1 | 2023 | 158 | 0.060 |
Why?
|
INDEL Mutation | 2 | 2015 | 279 | 0.060 |
Why?
|
Health Surveys | 1 | 2013 | 4037 | 0.060 |
Why?
|
bcl-X Protein | 1 | 2014 | 411 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2016 | 4385 | 0.060 |
Why?
|
HIV Infections | 1 | 2009 | 16718 | 0.060 |
Why?
|
Electric Power Supplies | 1 | 2023 | 99 | 0.050 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2023 | 298 | 0.050 |
Why?
|
Clinical Competence | 1 | 2018 | 4687 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 142 | 0.050 |
Why?
|
Chromosomal Instability | 1 | 2023 | 184 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7799 | 0.050 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 252 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2023 | 379 | 0.050 |
Why?
|
Arabs | 1 | 2023 | 178 | 0.050 |
Why?
|
Credentialing | 1 | 2022 | 126 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2022 | 288 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8628 | 0.050 |
Why?
|
Autocrine Communication | 1 | 2022 | 171 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8663 | 0.050 |
Why?
|
Disease-Free Survival | 3 | 2016 | 6893 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2020 | 2715 | 0.050 |
Why?
|
Child, Preschool | 3 | 2022 | 40992 | 0.050 |
Why?
|
Dactinomycin | 1 | 2020 | 317 | 0.050 |
Why?
|
Apoptosis | 1 | 2016 | 9728 | 0.050 |
Why?
|
Phthalazines | 1 | 2022 | 363 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2016 | 4252 | 0.040 |
Why?
|
Random Allocation | 1 | 2014 | 2427 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 20123 | 0.040 |
Why?
|
Cyclin E | 1 | 2020 | 172 | 0.040 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2021 | 374 | 0.040 |
Why?
|
Aneuploidy | 1 | 2023 | 530 | 0.040 |
Why?
|
Histocompatibility Antigens | 1 | 2021 | 471 | 0.040 |
Why?
|
DNA Methylation | 3 | 2019 | 4289 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2021 | 528 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 665 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6274 | 0.040 |
Why?
|
Kynurenine | 1 | 2019 | 138 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 380 | 0.040 |
Why?
|
Steroid 16-alpha-Hydroxylase | 1 | 2018 | 12 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2012 | 5021 | 0.040 |
Why?
|
Databases, Protein | 1 | 2021 | 383 | 0.040 |
Why?
|
Drugs, Investigational | 1 | 2021 | 214 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 552 | 0.040 |
Why?
|
Infant | 2 | 2022 | 35129 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 2538 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2020 | 537 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 9960 | 0.040 |
Why?
|
Dioxygenases | 1 | 2020 | 316 | 0.040 |
Why?
|
Melanoma-Specific Antigens | 1 | 2018 | 80 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2018 | 105 | 0.040 |
Why?
|
Chromatin | 2 | 2021 | 2934 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2021 | 359 | 0.040 |
Why?
|
Disease Models, Animal | 3 | 2021 | 18027 | 0.040 |
Why?
|
Tablets | 1 | 2018 | 147 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2021 | 618 | 0.040 |
Why?
|
Eukaryotic Initiation Factor-1 | 1 | 2017 | 33 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2021 | 326 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 933 | 0.040 |
Why?
|
Computer Graphics | 1 | 2019 | 360 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 793 | 0.040 |
Why?
|
Veterans | 1 | 2011 | 2519 | 0.040 |
Why?
|
Tryptophan | 1 | 2019 | 479 | 0.040 |
Why?
|
Entropy | 1 | 2018 | 209 | 0.040 |
Why?
|
Acetylation | 1 | 2020 | 1085 | 0.040 |
Why?
|
Single-Cell Analysis | 2 | 2019 | 2183 | 0.040 |
Why?
|
Estradiol | 1 | 2014 | 2020 | 0.040 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2018 | 257 | 0.040 |
Why?
|
Gene Duplication | 1 | 2018 | 330 | 0.040 |
Why?
|
Genes, myc | 1 | 2018 | 399 | 0.040 |
Why?
|
beta Catenin | 1 | 2022 | 1059 | 0.040 |
Why?
|
DNA | 2 | 2024 | 7303 | 0.040 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 195 | 0.040 |
Why?
|
Lymphocyte Activation | 2 | 2019 | 5523 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2014 | 2914 | 0.030 |
Why?
|
Open Reading Frames | 1 | 2019 | 810 | 0.030 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2018 | 658 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2505 | 0.030 |
Why?
|
Cell Line | 2 | 2022 | 15999 | 0.030 |
Why?
|
Fatigue | 1 | 2023 | 1531 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2017 | 351 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 1475 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1114 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2020 | 1401 | 0.030 |
Why?
|
Genes, Neurofibromatosis 2 | 1 | 2015 | 124 | 0.030 |
Why?
|
Fumarate Hydratase | 1 | 2015 | 47 | 0.030 |
Why?
|
Receptors, Purinergic P2Y | 1 | 2015 | 25 | 0.030 |
Why?
|
Unfolded Protein Response | 1 | 2017 | 233 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 3505 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3294 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 987 | 0.030 |
Why?
|
Anilides | 1 | 2018 | 405 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1223 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2020 | 2124 | 0.030 |
Why?
|
Oncogene Protein p21(ras) | 1 | 2015 | 82 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2032 | 0.030 |
Why?
|
Genes, p16 | 1 | 2015 | 157 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2018 | 940 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2018 | 671 | 0.030 |
Why?
|
Cytokines | 2 | 2021 | 7326 | 0.030 |
Why?
|
Kidney Tubules, Collecting | 1 | 2015 | 178 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 945 | 0.030 |
Why?
|
Genes, ras | 1 | 2017 | 690 | 0.030 |
Why?
|
Interferon Type I | 1 | 2018 | 542 | 0.030 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2020 | 986 | 0.030 |
Why?
|
Estrogens | 1 | 2021 | 1565 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1969 | 0.030 |
Why?
|
National Human Genome Research Institute (U.S.) | 1 | 2013 | 23 | 0.030 |
Why?
|
Cell Proliferation | 3 | 2015 | 10480 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2015 | 8860 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1097 | 0.030 |
Why?
|
Wnt Proteins | 1 | 2018 | 721 | 0.030 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2014 | 188 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1337 | 0.030 |
Why?
|
HeLa Cells | 1 | 2020 | 3129 | 0.030 |
Why?
|
Interferons | 1 | 2017 | 706 | 0.030 |
Why?
|
RNA, Neoplasm | 1 | 2016 | 769 | 0.030 |
Why?
|
United States | 4 | 2022 | 69867 | 0.030 |
Why?
|
Time Factors | 1 | 2015 | 40063 | 0.030 |
Why?
|
Safety | 1 | 2018 | 1185 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2540 | 0.030 |
Why?
|
DNA, Mitochondrial | 1 | 2018 | 817 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2022 | 2969 | 0.030 |
Why?
|
Cell Count | 1 | 2017 | 1854 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2018 | 1179 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2017 | 1880 | 0.030 |
Why?
|
Adaptation, Physiological | 1 | 2019 | 1312 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2020 | 1194 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1071 | 0.030 |
Why?
|
Muscle, Smooth | 1 | 2016 | 934 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2016 | 2839 | 0.030 |
Why?
|
Gene Deletion | 1 | 2020 | 2751 | 0.030 |
Why?
|
Haplotypes | 1 | 2018 | 2781 | 0.030 |
Why?
|
Leukocytes | 1 | 2020 | 2040 | 0.030 |
Why?
|
Europe | 1 | 2018 | 3339 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2019 | 2019 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1341 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2455 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2015 | 578 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2022 | 8302 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2017 | 828 | 0.020 |
Why?
|
Genetics, Medical | 1 | 2013 | 338 | 0.020 |
Why?
|
Stromal Cells | 1 | 2016 | 1355 | 0.020 |
Why?
|
Prevalence | 2 | 2019 | 15226 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2018 | 2008 | 0.020 |
Why?
|
Autophagy | 1 | 2018 | 1300 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1677 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2013 | 780 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2014 | 2030 | 0.020 |
Why?
|
Gene Frequency | 1 | 2016 | 3588 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2017 | 6313 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 2958 | 0.020 |
Why?
|
Pyridones | 1 | 2013 | 712 | 0.020 |
Why?
|
Workflow | 1 | 2013 | 847 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6535 | 0.020 |
Why?
|
Cell Communication | 1 | 2016 | 1621 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2013 | 2272 | 0.020 |
Why?
|
Demography | 1 | 2013 | 1656 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2575 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2013 | 1284 | 0.020 |
Why?
|
NF-kappa B | 1 | 2017 | 2501 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2015 | 1782 | 0.020 |
Why?
|
Protein Binding | 1 | 2021 | 9392 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39045 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2136 | 0.020 |
Why?
|
Genetic Markers | 1 | 2014 | 2634 | 0.020 |
Why?
|
Bone Marrow | 1 | 2018 | 2944 | 0.020 |
Why?
|
Cell Cycle | 1 | 2016 | 2967 | 0.020 |
Why?
|
Adolescent | 3 | 2022 | 85759 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5974 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3086 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3741 | 0.020 |
Why?
|
Patient Preference | 1 | 2013 | 887 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 12956 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4216 | 0.020 |
Why?
|
Registries | 1 | 2021 | 8090 | 0.020 |
Why?
|
Rats | 1 | 2022 | 24273 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9735 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 2915 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6765 | 0.020 |
Why?
|
Family | 1 | 2016 | 3148 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2016 | 13817 | 0.020 |
Why?
|
Base Sequence | 1 | 2016 | 12801 | 0.020 |
Why?
|
Liver | 1 | 2020 | 7472 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2015 | 3469 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2016 | 3478 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14556 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10949 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 25618 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 13036 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 21752 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 13990 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 21824 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 12075 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18367 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 20945 | 0.010 |
Why?
|
Risk Assessment | 1 | 2014 | 23337 | 0.010 |
Why?
|